title: Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study.
abstract: High-dose therapy with autologous blood progenitor cell support is now routinely used for patients with certain malignant lymphomas and multiple myeloma. We performed a prospective cost analysis of the mobilization, harvesting and cryopreservation phases and the high-dose therapy with stem cell reinfusion and hospitalization phases. In total, 40 consecutive patients were studied at four different university hospitals between 1999 and 2001. Data on direct costs were obtained on a daily basis. Data on indirect costs were allocated to the specific patient based on estimates of relevant department costs (ie the service department's costs), and by means of predefined allocation keys. All cost data were calculated at 2001 prices. The mean total costs for the two phases were US$ 32,160 (range US$ 19,092-50,550). The mean total length of hospital stay for two phases was 31 days (range 27-37). A large part of the actual cost in the harvest phase was attributed to stem cell mobilization, including growth factors, harvesting and cryopreservation. In the high-dose chemotherapy phase, the most significant part of the costs was nursing staff. Average total costs were considerably higher than actual DRG-based reimbursement from the government, indicating that the treatment of these patients was heavily subsidized by the basic hospital grants.
authors.affiliation: Health Professional Support Department, Rikshospitalet University Hospital, Oslo, Norway. vinod.mishra@rikshospitalet.no
authors.forename: V
authors.initials: V
authors.lastname: Mishra
authors.forename: S
authors.initials: S
authors.lastname: Andresen
authors.forename: L
authors.initials: L
authors.lastname: Brinch
authors.forename: S
authors.initials: S
authors.lastname: Kvaløy
authors.forename: P
authors.initials: P
authors.lastname: Ernst
authors.forename: M K
authors.initials: MK
authors.lastname: Lønset
authors.forename: J M
authors.initials: JM
authors.lastname: Tangen
authors.forename: J
authors.initials: J
authors.lastname: Wikelund
authors.forename: C
authors.initials: C
authors.lastname: Flatum
authors.forename: E
authors.initials: E
authors.lastname: Baggerød
authors.forename: B
authors.initials: B
authors.lastname: Helle
authors.forename: S
authors.initials: S
authors.lastname: Vaaler
authors.forename: T P
authors.initials: TP
authors.lastname: Hagen
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics; D003365:Costs and Cost Analysis; D015925:Cryopreservation / Q000191:economics; D016238:Cytapheresis / Q000191:economics; D005380:Financing, Government; D019650:Hematopoietic Stem Cell Mobilization / Q000191:economics; D006760:Hospitalization / Q000191:economics; D006801:Humans; D009664:Norway; D036102:Peripheral Blood Stem Cell Transplantation / Q000191:economics*; D011446:Prospective Studies; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents